65,437 trials
Methamphetamine Dependence · Methamphetamine Withdrawal
Primary: Methamphetamine Selective Severity Assessment (MSSA) — 48.2 "units on a scale" — p=<0.05
Psoriasis
Primary: Psoriasis Area and Severity Index 75 (PASI75) Response at Week 10 — 16 participants
Coronary Arteriosclerosis · Acute Coronary Syndrome
Primary: Maximum Platelet Aggregation (MPA) to 20 Micromolar (uM) Adenosine Diphosphase (ADP) — 41.1; 55.0; 41.0 percent maximum platelet aggregation (%) — p=<0.0001
Anemia
Primary: Patients With an Increase in Hemoglobin >= 1gm/dL. — 35; 23 participants
Diabetes
Primary: Percentage of Participants Rated as <=3 (Comprehension of Labeling) — 100; 100; 100; 100 percentage of participants
Diabetes Mellitus
Primary: Percent Change From Baseline in Glycosylated Hemoglobin — -1.83; -0.96; -0.99 percentage of Glycosylated Hemoglobin — p=<0.0001
Hypercholesterolemia · Diabetes Mellitus, Type 2 · Coronary Disease
Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint, After 6 Weeks of Treatment — -32.2; -20.8 percentage change — p=0.005
Sleep Disorders, Circadian Rhythm
Primary: Latency to Persistent Sleep Over a 2-night Average Measured by Polysomnography (Nights 6-7) — 59.30; 39.40; 55.94; 55.12 minutes — p=0.646
Cervical Cancer · Genital Warts
Primary: Number of Subjects Who Seroconverted for HPV 6 by Week 4 Postdose 3 — 423; 428; 320; 0 Subjects — p=<0.001
Hepatitis A
Primary: Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration — 748.1; 378.6; 419.3; 342.2 mIU/mL
Neoplasms, Prostate
Primary: Number of Participants With Biopsy-detectable Prostate Cancer at Years 2 and 4 (Crude Rate Approach) — 578; 435; 280; 224 participants — p=<0.0001
Type 2 Diabetes Mellitus (T2DM)
Primary: Change From Baseline in Glucagon 3-hour Total Area Under the Curve (AUC) After 12 Weeks of Treatment — -17.2; -4.9; -29.8; 12.5 pg*hr/mL — p=0.002
Infections, Papillomavirus
Primary: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 337; 342; 345; 346…
Hypertension · Metabolic Syndrome X
Primary: Response Rate at the End of 30 Day Period — 41.4; 66.3; 31.2 Percentage of patients
Endotracheal Intubation · Supraglottic Airway
Primary: Duration of Intubation — 30.9; 30.8; 30.17 seconds